CCM
CSTL icon

Chiron Capital Management’s Castle Biosciences CSTL Stock Holding History

Chiron Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-350
Closed -$18K – 156
2020
Q3 		$18K Buy
+350
New +$15.6K 0.01% 234

Other funds holding CSTL

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Chiron Capital Management's CSTL Position: Q4 2020 in Review

Chiron Capital Management sold out of Castle Biosciences (CSTL) in Q4 2020, closing a stake of 350 shares — an estimated $18K sold.

Chiron Capital Management first reported a position in CSTL in Q3 2020 and held it in 1 quarter. The position peaked at $18K in Q3 2020. 163 funds tracked by Wall St. Rank hold CSTL as of Q4 2020.

  • Chiron Capital Management reported no remaining Castle Biosciences position as of Q4 2020 after selling out during the quarter.
  • Chiron Capital Management sold 350 Castle Biosciences shares in Q4 2020, an estimated $18K.
  • Chiron Capital Management first reported a position in Castle Biosciences in Q3 2020 and held it in 1 quarter.
  • Chiron Capital Management's Castle Biosciences position peaked at $18K in Q3 2020.
  • 163 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2020.

Based on Chiron Capital Management's 13F filing for Q4 2020, filed 5 Mar 2021.